search
Back to results

Interventions for Reading Disabilities in NF1

Primary Purpose

Neurofibromatosis Type 1, Learning Disability, Reading Disability

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Lovastatin
reading tutoring intervention
Placebo Oral Tablet
Other Academic "sham" tutoring
Sponsored by
Vanderbilt University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neurofibromatosis Type 1 focused on measuring Neurofibromatosis Type 1, Learning Disability, Reading Disability, NF1

Eligibility Criteria

8 Years - 20 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

This study will be open to all English speakers who meet eligibility criteria regardless of race, gender, minority or socioeconomic status. Inclusion criteria to be met are listed below:

  1. Individuals ages 8-20 (all participants)
  2. Documented NF-1 (NF patients only)
  3. If female, participant is post-menarche (NF patients only)
  4. If male, participant has reached Tanner Stage 2 (NF patients only)
  5. Participant able to swallow capsule (NF patients only, may be confirmed via swallowability test, described below)
  6. Participant's English is sufficient for school (all participants)
  7. Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions B-D listed below:

A. Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability? Swallowability Assessment: We may ask patients to perform a capsule swallowability assessment prior to enrollment. We will ask subjects to attempt to swallow an empty capsule, matching the same size of the Lovastatin 20mg and 40mg capsules to be used in the study, to confirm swallowability. Patients will be provided with up to 2 capsules as needed to successfully perform the swallowability assessment. If the patient is unable to swallow the capsule, enrollment in the study may deferred or declined.

A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing:

  1. Child 7 years of age or less;
  2. known uncorrectable visual impairment;
  3. documented hearing impairment greater than or equal to a 25 dB loss;
  4. medical contraindication to MRI procedures (e.g., metal devices);
  5. any psychiatric, behavioral, or developmental disorder that would preclude active participation in in-depth tutoring sessions
  6. Pregnant at time of screening.
  7. Known conditions which are contraindicated to Lovastatin

    1. Hypersensitivity to the medication
    2. Uncontrolled Epilepsy
    3. Metabolic Syndrome X, High Blood Sugar,
    4. Muscle Damage Due to Autoimmunity
    5. Stroke caused by Bleeding in the Brain, Loss of Memory,
    6. Severely Low Blood Pressure
    7. Liver Problems including Abnormal Liver Function Tests
    8. Severe Renal Impairment,
    9. Serious Muscle Damage that may Lead to Kidney Failure,
    10. Recent Operation or significant Injury
    11. Muscle Pain or Tenderness with Increase Creatinine Kinase,
    12. Habit of Drinking Too Much Alcohol
    13. Pregnant or lactating. - Lovastatin is contraindicated during pregnancy and in nursing mothers because it decreases synthesis of cholesterol and other products of the cholesterol biosynthesis pathway that are essential components for fetal development.

Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild depression will be eligible as long as they are not taking psychotropic medications, with the exception of stimulant medication for ADHD.

For pilot participants only:

Criteria for inclusion/exclusion for pilot participants is outlined below. Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild depression will be eligible as long as they are not taking psychotropic medications, with the exception of stimulant medication for ADHD.

  1. Children ages 8-17
  2. Participant is a native English speaker
  3. Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions 2-4 listed below:

A. Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability?

A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing:

  1. Children 7 years of age or younger
  2. previous diagnosis of Intellectual Disability;
  3. known uncorrectable visual impairment;
  4. documented hearing impairment greater than or equal to a 25 dB loss;
  5. medical contraindication to MRI procedures (e.g., metal devices);
  6. known IQ below 70;
  7. a pervasive developmental disorder; and
  8. any known neurologic pathology, including epilepsy, spina bifida, cerebral palsy, traumatic brain injury, optic gliomas, and brain tumors (other than UBOs).
  9. Comorbid severe psychiatric disorders will also be excluded.

Sites / Locations

  • Vanderbilt UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Placebo Comparator

Sham Comparator

Arm Label

NF1: Lovastatin + reading tutoring

NF1: Placebo + reading tutoring

RD: Reading tutoring

RD: Other Academic (sham) tutoring

Arm Description

Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks. And one week of intensive, one-on-one reading tutoring intervention

Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention

Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention

Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading. These participants will have the opportunity to receive reading tutoring upon finishing study participation.

Outcomes

Primary Outcome Measures

Woodcock Johnson Tests of Achievement IV
WJ-IV (Forms A and B) Letter Word Identification, Word Attack, and Passage Comprehension subtests will be administered in order to assess word recognition accuracy, decoding accuracy, and comprehension.
Woodcock Reading Mastery Test-III
(WRMT-III; Forms A and B); Word Identification, Word Attack, and Passage Comprehension will be administered to assess word recognition accuracy, decoding accuracy, and comprehension. The WRMT-III and WJ-III correlate at .87, and at the item level show similar characteristics (e.g., containing 31% and 34% multisyllabic words, respectively).
Test of Word Reading Efficiency-2
(TOWRE-2; Forms A, B, C, D) Sight Word Efficiency and Pseudoword Decoding will be used to assess real and pseudoword reading speed.
Experimental Word and Pseudoword Lists
At each visit, 2 word and 2 pseudoword lists (20 words each) will be administered. Word lists are matched on relevant characteristics (e.g., frequency, bigram frequency). Real word lists have already been developed and tested, and show high inter-correlations (r =.87-.97).
Test of Silent Contextual Reading Fluency-2
(TOSCRF-2; 91; Forms A, B, C, D). This test requires identifying as many words as possible in 3 min within a sentential context.
Comprehensive Test of Phonological Processing-2
CTOPP-2 core subtests will be used to assess phonological processing, a known predictor of decoding and word recognition.
Delis Kaplan Executive Function System
Sorting from the D-KEFS will be used to assess higher-level planning and shifting abilities.
Visuospatial Learning and Memory, Morris Water Maze
The child "hops" from square to square in the grid, repeated from various starting points. After landing on the target square, a fun goal pops up. The number of "hops" to reach the goal is measured. A control probe trial is given in which there is no goal.
Visuospatial Learning and Memory, Judgment of Line Orientation
(JLO, Forms J and H)98 requires the judgment of spatial relationships between two lines compared to a reference of a protractor-like half-circle of 11 lines. The Investigator will create 4 forms from the two already existing by splitting each test in half by selecting every other item, a method used by others (Leach et al., 2003). This will allow us to generate 4 different versions of the JLO.
Clinical Evaluation of Language Fundamentals-Fifth Edition
CELF-5 will be used to assess aspects of oral language (e.g., syntax, semantics, & working memory).

Secondary Outcome Measures

Full Information

First Posted
November 9, 2016
Last Updated
July 20, 2023
Sponsor
Vanderbilt University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT02964884
Brief Title
Interventions for Reading Disabilities in NF1
Official Title
Neurobiology and Treatment of Reading Disability in NF1
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 2016 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can respond to standard phonologically-based reading tutoring originally developed to treat reading disability in the general population. Combining our work with that by other researchers suggesting that a medication (Lovastatin) may counteract the effects of the deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the investigator propose to examine the synergistic effects of medication plus reading tutoring.
Detailed Description
Neurofibromitosis Type 1 (NF1) is a common autosomal dominant neurocutaneous syndrome. The most common concern of NF1 is learning disabilities (LDs). Approximately half of children with NF1 have LDs, the most common of which are reading disabilities (RDs).The purpose of this research is to gain a deeper understanding of the characteristics and treatment of RDs in NF1. The Investigator will evaluate four different groups (see list below) to determine if there are differential outcomes in these groups of children with NF+RD. The first two groups will consist of NF1 patients, and the second two groups will consist of participants with RDs but without NF1. Reading tutoring program and a medication called Lovastatin (NF1 patients) Reading tutoring program and no Lovastatin (placebo) (NF1 patients) Reading tutoring program (RD participants) Other Academic "Sham" tutoring (eligible to receive reading tutoring after study participation is complete) (RD participants)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurofibromatosis Type 1, Learning Disability, Reading Disability, NF1
Keywords
Neurofibromatosis Type 1, Learning Disability, Reading Disability, NF1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NF1: Lovastatin + reading tutoring
Arm Type
Active Comparator
Arm Description
Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks. And one week of intensive, one-on-one reading tutoring intervention
Arm Title
NF1: Placebo + reading tutoring
Arm Type
Placebo Comparator
Arm Description
Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
Arm Title
RD: Reading tutoring
Arm Type
Placebo Comparator
Arm Description
Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
Arm Title
RD: Other Academic (sham) tutoring
Arm Type
Sham Comparator
Arm Description
Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading. These participants will have the opportunity to receive reading tutoring upon finishing study participation.
Intervention Type
Drug
Intervention Name(s)
Lovastatin
Intervention Description
Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
Intervention Type
Behavioral
Intervention Name(s)
reading tutoring intervention
Intervention Description
After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
Intervention Type
Drug
Intervention Name(s)
Placebo Oral Tablet
Intervention Description
Those in the placebo group will receive a tablet daily
Intervention Type
Behavioral
Intervention Name(s)
Other Academic "sham" tutoring
Intervention Description
No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
Primary Outcome Measure Information:
Title
Woodcock Johnson Tests of Achievement IV
Description
WJ-IV (Forms A and B) Letter Word Identification, Word Attack, and Passage Comprehension subtests will be administered in order to assess word recognition accuracy, decoding accuracy, and comprehension.
Time Frame
24 weeks
Title
Woodcock Reading Mastery Test-III
Description
(WRMT-III; Forms A and B); Word Identification, Word Attack, and Passage Comprehension will be administered to assess word recognition accuracy, decoding accuracy, and comprehension. The WRMT-III and WJ-III correlate at .87, and at the item level show similar characteristics (e.g., containing 31% and 34% multisyllabic words, respectively).
Time Frame
24 weeks
Title
Test of Word Reading Efficiency-2
Description
(TOWRE-2; Forms A, B, C, D) Sight Word Efficiency and Pseudoword Decoding will be used to assess real and pseudoword reading speed.
Time Frame
24 weeks
Title
Experimental Word and Pseudoword Lists
Description
At each visit, 2 word and 2 pseudoword lists (20 words each) will be administered. Word lists are matched on relevant characteristics (e.g., frequency, bigram frequency). Real word lists have already been developed and tested, and show high inter-correlations (r =.87-.97).
Time Frame
24 weeks
Title
Test of Silent Contextual Reading Fluency-2
Description
(TOSCRF-2; 91; Forms A, B, C, D). This test requires identifying as many words as possible in 3 min within a sentential context.
Time Frame
24 weeks
Title
Comprehensive Test of Phonological Processing-2
Description
CTOPP-2 core subtests will be used to assess phonological processing, a known predictor of decoding and word recognition.
Time Frame
24 weeks
Title
Delis Kaplan Executive Function System
Description
Sorting from the D-KEFS will be used to assess higher-level planning and shifting abilities.
Time Frame
24 weeks
Title
Visuospatial Learning and Memory, Morris Water Maze
Description
The child "hops" from square to square in the grid, repeated from various starting points. After landing on the target square, a fun goal pops up. The number of "hops" to reach the goal is measured. A control probe trial is given in which there is no goal.
Time Frame
24 weeks
Title
Visuospatial Learning and Memory, Judgment of Line Orientation
Description
(JLO, Forms J and H)98 requires the judgment of spatial relationships between two lines compared to a reference of a protractor-like half-circle of 11 lines. The Investigator will create 4 forms from the two already existing by splitting each test in half by selecting every other item, a method used by others (Leach et al., 2003). This will allow us to generate 4 different versions of the JLO.
Time Frame
24 weeks
Title
Clinical Evaluation of Language Fundamentals-Fifth Edition
Description
CELF-5 will be used to assess aspects of oral language (e.g., syntax, semantics, & working memory).
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: This study will be open to all English speakers who meet eligibility criteria regardless of race, gender, minority or socioeconomic status. Inclusion criteria to be met are listed below: Individuals ages 8-20 (all participants) Documented NF-1 (NF patients only) If female, participant is post-menarche (NF patients only) If male, participant has reached Tanner Stage 2 (NF patients only) Participant able to swallow capsule (NF patients only, may be confirmed via swallowability test, described below) Participant's English is sufficient for school (all participants) Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions B-D listed below: A. Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability? Swallowability Assessment: We may ask patients to perform a capsule swallowability assessment prior to enrollment. We will ask subjects to attempt to swallow an empty capsule, matching the same size of the Lovastatin 20mg and 40mg capsules to be used in the study, to confirm swallowability. Patients will be provided with up to 2 capsules as needed to successfully perform the swallowability assessment. If the patient is unable to swallow the capsule, enrollment in the study may deferred or declined. A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing: Child 7 years of age or less; known uncorrectable visual impairment; documented hearing impairment greater than or equal to a 25 dB loss; medical contraindication to MRI procedures (e.g., metal devices); any psychiatric, behavioral, or developmental disorder that would preclude active participation in in-depth tutoring sessions Pregnant at time of screening. Known conditions which are contraindicated to Lovastatin Hypersensitivity to the medication Uncontrolled Epilepsy Metabolic Syndrome X, High Blood Sugar, Muscle Damage Due to Autoimmunity Stroke caused by Bleeding in the Brain, Loss of Memory, Severely Low Blood Pressure Liver Problems including Abnormal Liver Function Tests Severe Renal Impairment, Serious Muscle Damage that may Lead to Kidney Failure, Recent Operation or significant Injury Muscle Pain or Tenderness with Increase Creatinine Kinase, Habit of Drinking Too Much Alcohol Pregnant or lactating. - Lovastatin is contraindicated during pregnancy and in nursing mothers because it decreases synthesis of cholesterol and other products of the cholesterol biosynthesis pathway that are essential components for fetal development. Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild depression will be eligible as long as they are not taking psychotropic medications, with the exception of stimulant medication for ADHD. For pilot participants only: Criteria for inclusion/exclusion for pilot participants is outlined below. Children who meet criteria for ADHD, Oppositional Defiant Disorder, adjustment disorder, and/or mild depression will be eligible as long as they are not taking psychotropic medications, with the exception of stimulant medication for ADHD. Children ages 8-17 Participant is a native English speaker Participant must either answer "yes" to question A, or answer "yes" to at least 2 items for questions 2-4 listed below: A. Has your child ever been diagnosed with a reading disability? B. Did your child have trouble learning how to "sound out" words? C. Have you (parent) ever been concerned about your child's reading ability? D. Did the school or teacher ever express any concerns about your child's reading ability? A child will be excluded if he/she meets any of the following criteria, which will be determined by initial telephone screening as well as review of medical/developmental history prior to and during testing: Children 7 years of age or younger previous diagnosis of Intellectual Disability; known uncorrectable visual impairment; documented hearing impairment greater than or equal to a 25 dB loss; medical contraindication to MRI procedures (e.g., metal devices); known IQ below 70; a pervasive developmental disorder; and any known neurologic pathology, including epilepsy, spina bifida, cerebral palsy, traumatic brain injury, optic gliomas, and brain tumors (other than UBOs). Comorbid severe psychiatric disorders will also be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Julie Delheimer, BS
Phone
615-875-5534
Email
educationbrain@vanderbilt.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Lanier P. Sachs, M.E.d
Phone
615-936-1167
Email
virginia.l.prichard@vanderbilt.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laurie Cutting, PhD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sheryl L. Rimrodt-Frierson, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Vanderbilt University
City
Nashville
State/Province
Tennessee
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura E. Cutting
Phone
615-875-1054

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Interventions for Reading Disabilities in NF1

We'll reach out to this number within 24 hrs